Skip to main content
CBIO logo

CBIO · Crescent Biopharma, Inc. · Holdings

Track CBIO — free
$13.00 +0.09 (+0.70%) At close · Nov 20
Market Cap
$505.64M
Shares
38.90M
Volume · Nov 20 422.38K Avg daily vol (3M) 358.97K

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

Holders: 105
Total Value: $589,676,815
Total Shares: 40,416,510
Showing 1–100 of 106 holdings by value · page 1 of 2

Institutional Ownership Trend

6 quarters

Holder Concentration

Share of 13F common-share value, across 105 filers with any position, options included · Δ vs Jun 30, 2026
Top Holder
14.6%
Jun 2025 → Sep 2026 · range 12.5% – 17.4%
+0.4 pts
Top 5
43.9%
Jun 2025 → Sep 2026 · range 43.9% – 57.9%
−3.0 pts
Top 10
65.4%
Jun 2025 → Sep 2026 · range 65.4% – 79.9%
−7.5 pts
HHI
581
Jun 2025 → Sep 2026 · range 581 – 863
Broadly held−73

Who Holds CBIO

Last 6 quarters through Sep 30, 2026

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Sep 30, 2026: 105 filers, like-for-like change +38.8%; actively managed books +32.5%; index-like books +91.6%.

Holder type Share Filers Change
Registered adviser 51.0% 54 +28.2%
Exempt adviser 1.1% 3 +57.9%
Adviser 4.3% 3 +364.9%
Bank 3.7% 10 +95.8%
Insurer 0.1% 1 new
Benefit plan 0.0% 1 0.0%
Non-US 0.0% 2 -19.1%
Holding company 20.7% 6 +53.9%
Broker-dealer 0.0% 0 —
Unknown 19.1% 25 +25.2%
How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Excluded 1 holder with no observed 2026-06-30 13F.

Conviction and Crowding

105 13F filers, quarter ended Sep 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
3
2.86% of filers hold it in their top 10
Jun 30, 2026: 3
Holders above 5%
0
median weight 0.001%
Jun 30, 2026: 0
Crowding
—
holders exceed shares outstanding: 13F filers report more shares than the cover-page count, which predates an issuance, is misstated, or misses shares lent and reported twice
Private-fund advisers
—
of shares outstanding
Institutional ownership
—
holders exceed shares outstanding: 13F filers report more shares than the cover-page count, which predates an issuance, is misstated, or misses shares lent and reported twice
Top 10 holders
65.4%
of 13F shares, Herfindahl 0.058
Active holders
+32.5%
like-for-like share change of active filers
5% stakes on record
7
1 13D, 6 13G (3 institutional, 3 passive, 0 exempt)
How long holders have held it value-weighted 4.6 quarters
Under 1 year 21.2% 1 to 3 years 78.8% 3 years or more 0.000% Since coverage start 0.000%

Managers in the top fifth by current three-year FundScore alpha were net buyers of $81,360,034 (12 buying, 3 selling).

Estimated Holder Cost Basis

Quarter ended Sep 30, 2026, on that quarter's share basis

Estimated, never filed: each 13F buy is costed at its quarter's average traded price and each sale keeps the average cost, so this is what holders paid on average if they traded evenly through each quarter.

Estimated avg cost
$15.48
estimated per share
Jun 30, 2026: $14.29
Quarter-end price
$14.59
implied by 13F values
Estimated gain or loss
-5.7%
price against the estimated cost
Estimated at a loss
67.6%
of costed 13F value

Estimated cost covers 46.0% of the 13F shares; positions already held when a filer's 13F history starts, or bought in a quarter without a trusted average price, have no estimate.

Shared Holders

Companies CBIO's active holders also own, quarter ended Sep 30, 2026
# Company Shared holders
1 DMRA Damora Therapeutics, Inc. 9
2 PALI Palisade Bio, Inc. 8
3 JBIO Jade Biosciences, Inc. 8
4 KRSA Korsana Biosciences, Inc. 7
5 ADRX ADARx Pharmaceuticals, Inc. 6
6 ANL Adlai Nortye Group Ltd. 6
7 IRON Disc Medicine, Inc. 8
8 IMTX Immatics N.V. 6
9 ENGN enGene Therapeutics Inc. 6
10 ENTX Entera Bio Ltd. 6

Shareholder Targets

13F filers that own its peers but not CBIO, quarter ended Sep 30, 2026

Found through its holder-overlap peers: DMRA, PALI, JBIO, KRSA, ADRX, ANL, IRON, IMTX, ENGN, ENTX, COGT, OLMA, VYGR, DYN, ORIC, STOK, ACOG, IVVD, RZLT, TNGX. 570 filers in all.

# Filer In peers
1 T. Rowe Price Investment Management, Inc. Adviser, Diversified active $894,025,665 5 held
2 JANUS HENDERSON GROUP PLC Adviser, Diversified active $832,725,918 12 held
3 TCG Crossover Management, LLC Unknown, Diversified active $674,556,370 7 held
4 ORBIMED ADVISORS LLC Registered adviser, Diversified active $656,669,166 5 held
5 DEERFIELD MANAGEMENT COMPANY, L.P. Registered adviser, Diversified active $410,402,360 4 held
6 Paradigm Biocapital Advisors LP Registered adviser, Concentrated $374,012,719 5 held
7 RA CAPITAL MANAGEMENT, L.P. Registered adviser, Concentrated $330,712,767 8 held
8 FRANKLIN RESOURCES INC Adviser, Diversified active $282,636,266 9 held
9 Polar Capital Holdings Plc Registered adviser, Diversified active $281,558,785 5 held
10 SR One Capital Management, LP Registered adviser, Concentrated $281,447,022 4 held

Fund Ownership of CBIO by Fund Type

Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026

Index funds and index ETFs hold 2.01% of shares outstanding.

Fund type Of shares outstanding Shares
Index funds 0.09% 34,762
Index ETFs 1.92% 745,747
Active ETFs 0.00% 0
Active funds 0.00% 0
Unclassified 0.04% 15,612
All registered funds 2.05% 796,121
How fund types are measured

Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.

Quarterly Activity

vs Jun 30, 2026
New
37
Increased
45
Decreased
12
Sold Out
13
Unchanged
10

New and Sold Out count only filers that reported a 13F for both quarters: a first-time filer's book is not a buy, and a fund that has not filed, or withheld its positions under confidential treatment, has not sold.

Holder count: +25
Institutional value: +12.5%
Shares held: +38.8%

Top Buyers

vs Jun 30, 2026
Institution Added Now Holds Open

Top Sellers

vs Jun 30, 2026
Institution Sold Now Holds Open

Top New Positions

vs Jun 30, 2026
Institution Acquired Value (USD) Open

Top Sold-Out Positions

vs Jun 30, 2026
Institution Previously Held Last Value (USD) Open
Showing 100 of 106
Export CSV
Holder Value (USD) % of 13F Shares Own % Change Type Filed Open

Showing the top 100 of 106 holders. Create a free account to see every holder, past quarters, search, filters and CSV export.

Key facts CIK 1253689 CUSIP G2545C104 13F (30d) 102 filings 99 filers Visit website Investor relations